FNY Investment Advisers’s Cytokinetics CYTK Stock Holding History

FNY Investment Advisers’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$170K	Sell	2,000 -7,030	-78%	-$505K	0.06%	260
2026 Q1	$595K	Buy	9,030 +3,770	+72%	+$240K	0.26%	96
2025 Q4	$334K	Sell	5,260 -3,354	-39%	-$209K	0.09%	175
2025 Q3	$473K	Sell	8,614 -4,281	-33%	-$176K	0.15%	168
2025 Q2	$426K	Buy	12,895 +2,040	+19%	+$71K	0.18%	136
2025 Q1	$436K	Sell	10,855 -3,690	-25%	-$170K	0.27%	85
2024 Q4	$684K	Buy	14,545 +3,240	+29%	+$168K	0.35%	67
2024 Q3	$596K	Sell	11,305 -768	-6%	-$42.8K	0.29%	89
2024 Q2	$654K	Buy	12,073 +2,018	+20%	+$122K	0.44%	47
2024 Q1	$704K	Buy	+10,055	New	+$778K	0.42%	59

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FNY Investment Advisers's CYTK Position: Q2 2026 in Review

FNY Investment Advisers reduced its Cytokinetics (CYTK) stake by 78% in Q2 2026, selling an estimated $505K and leaving 2,000 shares worth $170K. The position accounts for 0.06% of the portfolio, ranked #260.

FNY Investment Advisers first reported a position in CYTK in Q1 2024 and has held it in 10 quarters since. The position peaked at $704K in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

FNY Investment Advisers held 2,000 shares of Cytokinetics worth $170K as of Q2 2026.
FNY Investment Advisers sold 7,030 Cytokinetics shares in Q2 2026, an estimated $505K.
Cytokinetics made up 0.06% of FNY Investment Advisers's portfolio in Q2 2026, its #260 holding.
FNY Investment Advisers first reported a position in Cytokinetics in Q1 2024 and has held it in 10 quarters since.
FNY Investment Advisers's Cytokinetics position peaked at $704K in Q1 2024.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.